| Literature DB >> 29937481 |
Ashely Bennett1, Michelle M Ponder2, Julia Garcia-Diaz3,4.
Abstract
Phoma species are phytopathogens that are widely distributed in the environment, most commonly found in aquatic systems and soil. Phoma spp. have the potential to be pathogenic in plants, animals and humans; the latter is a rare occurrence. However, as our immunocompromised population increases, so do the reports of these infections. Medical advances have allowed for the increase in solid organ transplantation; chemotherapies to treat malignancies; and the use of other immunosuppressive agents, which have resulted in a greater population at risk when exposed to diverse fungi including Phoma spp. These fungi have been isolated from water sources, food, and crops; thus acting as opportunistic pathogens when the right host is exposed. Phoma spp. contaminates common food sources such as potatoes and maize, a common species isolated being Phoma sorghina. Though there is potential for causing infection via consumption of contaminated foods, there is insufficient data detailing what levels of organism can lead to an infection, and a regulated process for detecting the organism. The spectrum of disease is wide, depending on the host, ranging from cutaneous infections to invasive diseases. Mortality, however, remains low.Entities:
Keywords: Phoma spp.; food; phaeohyphomycosis; subcutaneous mycosis
Year: 2018 PMID: 29937481 PMCID: PMC6165263 DOI: 10.3390/microorganisms6030058
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Phoma species schema based on current classification data utilizing morphologic and molecular characterization data. (1) Basidiomycota and Ascomycota are more closely related to one another than to other phyla. (2) Use of molecular based phylogenetic analyses has restricted the Phoma genus to Phoma herbarum sp. within family Didymellaceae.
Infections Caused by Phoma spp. in Humans.
| Isolated Fungus | Gender/Age | Source/History | Immunosuppression | Treatment/Outcome | Reference |
|---|---|---|---|---|---|
| N/A | Pulmonary | N/A | N/A | Janke, D. et al. 1956 [ | |
| F/22 | Skin (deep leg) | Topical steroids | Oral griseofulvin/clinical improvement | Bakerspigel, A. 1970 [ | |
| F/42 | Skin (deep heel) | Azathioprine; prednisone; | Debridement/resolved | Young, N.A. et al. 1973 [ | |
| M/4 | Skin (superficial ear) | Otherwise healthy | Oral griseofulvin; corticosteroid/resolved | Gordon, M.A. et al. 1975 [ | |
| N/A | Eye (Corneal ulcer) | Otherwise healthy | N/A | Punithalingam, E. 1976 [ | |
| F/? | Subcutaneous | N/A | N/A | Punithalingam, E. 1979 [ | |
| M/18 mos. | Skin (perioral lesions) | Otherwise healthy | Clotrimazole; | Bakerspigel, A. et al. 1981 [ | |
| M/18 | Skin (face) | Typhoid fever | Topical clotrimazole/resolved | Shukla, N.P. et al. 1984 [ | |
| M/75 | Skin (deep foot) | Steroid therapy | Debridement; amputation for secondary gangrene/resolved | Baker, J.G. et al. 1987 [ | |
| M/24 | Skin (face, neck, hands) | Otherwise healthy | Topical miconazole/resolved | Rai, M.K. 1989 [ | |
| F/24 | Pulmonary (lung mass) | Acute Lymphocytic Leukemia; chemotherapy | Left lower lobectomy Amphotericin B/resolved | Morris, J.T. et al. 1995 [ | |
| M/45 | Skin (deep/hands) | Otherwise healthy | Itraconazole; ketoconazole/clinical improvement | Hirsh, A.H. et al. 1996 [ | |
| F/24 | Skin (deep face) | Topical steroids | Ketoconazole/resolved | Rosen, T. et al. 1996 [ | |
| M/63 | Skin (deep hand) | Pulmonary sarcoidosis; oral steroids | Amphotericin B; itraconazole/resolved | Zaitz, C. et al. 1997 [ | |
| M/49 | Skin (plantar; foot) | Atopic dermatitis | Topical bifonazole and ketoconazole/No improvement; lost to follow up | Arrese, J.E. et al. 1997 [ | |
| M/77 | Skin (deep) | Otherwise healthy | Itraconazole/resolved | Oh, C.K. et al. 1999 [ | |
| M/72 | Eye (keratitis) | Otherwise healthy | Debridement; keratectomy | Rishi, K. et al. 2003 [ | |
| F/50 | Skin (deep hand) | s/p renal transplant | Surgical debridement; | Everett, J.E. et al. 2003 [ | |
| M/19 | Skin (deep face) | N/A | Amphotericin B | Suh, M.K. 2005 [ | |
| M/68 | Pulmonary | Acute myeloid leukemia; Diabetes mellitus | Amphotericin B; left pneumonectomy/death | Balis, E. et al. 2006 [ | |
| M/32 | Eye (endophthalmitis) | None noted | Amphotericin (intravitreal); voriconazole (intravitreal)/resolved | Errera, M.H. et al. 2008 [ | |
| F/36 | Nail, toe | Otherwise healthy | Allylamine; sertaconazole/resolved | Tullio, V. et al. 2010 [ | |
| M/69 | Skin (ganglion cysts on wrist, forearm) | Diabetes mellitus | Oral itraconazole; surgical excision/resolved | Vasoo, S. et al. 2011 [ | |
| F/1 mo. | Sinus (invasive rhinosinusitis) | Acute lymphoblastic leukemia; | Amphotericin B; posaconazole; voriconazole; debridement/death with progressive rhinocerebral extension | Roehm, C.E. et al. 2012 [ | |
| M/45 | Skin (deep knee) | Diabetes mellitus; s/p liver transplant | Oral ketoconazole; surgical excision | Schieffelin, J.S. et al. 2014 [ | |
| F/79 | Eye (keratitis) | Otherwise healthy | Oral itraconazole; amphotericin eye (intravitreal); keratoplasty/resolved | Kumar, P. et al. 2015 [ | |
| F/59 | Eye (corneal ulcer and abscess) | Otherwise healthy | Amphotericin B; (intravitreal); keratoplasty | McElnea, E. et al. 2015 [ | |
| M/79 | Skin (deep foot) | Chronic alcoholism, smoker | None/lost to follow up | Hernández-Hernández, F. et al. 2018 [ |
Results of in vitro Susceptibilities of Systemic Antifungals to Phoma spp.
| Organism | Value for the Drug (Microgram/mL) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMB 1 | 5-FC | ITC | VRC | FLC | PSC | KTC | TRB | MFG | CFG | AFG | MON | NAT | |
| Valenzuela-Lopez, N. et al. 2017 [ | |||||||||||||
| 0.03–4 | 0.5–16 | 0.03–2 | 0.03–2 | -- | 0.03–1 | -- | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.03 | -- | -- | |
| 0.12–2 | 0.5–16 | 0.25–4 | 0.06–4 | -- | 0.12–1 | -- | ≤0.03 | 0.03–0.06 | 0.03–0.12 | 0.03–0.12 | -- | -- | |
| Sutton, D.A. 1999 [ | |||||||||||||
| 1 | 16 | 16 | -- | 32 | -- | 8 | -- | -- | -- | -- | 8 | 32 | |
1 Abbreviations are as follows: AMB: amphotericin B, ITC: itraconazole, 5-FC: 5-fluorocytosine, VRC: voriconazole, FLC: fluconazole, POSA: posaconazole, KTC: ketoconazole, TRB: terbinafine, MFG: micafungin, CFG: caspofungin, AFG: anidulafungin, MON: miconazole, NAT: natamycin/pimaracin. 2 Range: MIC90: minimum inhibitory concentration of drug that inhibited 90% of isolates, MIC: minimum inhibitory concentration, --: Not performed. 3 Breakpoint: chosen concentration of an antibiotic which defines whether a species of bacteria is susceptible or resistant to the antibiotic, S = susceptible, R = susceptible. 4 Values < 32 presumed susceptible.